Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
0.514
+0.032 (6.58%)
At close: Nov 20, 2024, 4:00 PM
0.520
+0.006 (1.17%)
After-hours: Nov 20, 2024, 6:56 PM EST
Passage Bio Employees
Passage Bio had 58 employees as of December 31, 2023. The number of employees decreased by 27 or -31.76% compared to the previous year.
Employees
58
Change (1Y)
-27
Growth (1Y)
-31.76%
Revenue / Employee
n/a
Profits / Employee
-$1,186,207
Market Cap
31.73M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58 | -27 | -31.76% |
Dec 31, 2022 | 85 | -48 | -36.09% |
Dec 31, 2021 | 133 | 59 | 79.73% |
Dec 31, 2020 | 74 | 54 | 270.00% |
Dec 31, 2019 | 20 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Pluri | 118 |
IRIDEX | 111 |
ImmuCell | 79 |
Spectral AI | 78 |
IceCure Medical | 77 |
AN2 Therapeutics | 41 |
MiNK Therapeutics | 31 |
Daré Bioscience | 26 |
PASG News
- 15 days ago - Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 4 weeks ago - Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference - GlobeNewsWire
- 2 months ago - Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference - GlobeNewsWire
- 2 months ago - Passage Bio Welcomes Tom Kassberg to Board of Directors - GlobeNewsWire
- 2 months ago - Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewsWire
- 4 months ago - Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration - GlobeNewsWire
- 4 months ago - Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients - GlobeNewsWire